Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system

Bibliography

• van den Heuvel MW, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72(3):168-74
   PubMed Web of Science ®Google Scholar
• Archer DF, Cullins V, Creasy GW, et al. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004;69(3):189-95
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013;4:CD003552
   PubMedGoogle Scholar
• Devineni D, Skee D, Vaccaro N, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 2007;47(4):497-509
   PubMed Web of Science ®Google Scholar
• Cole JA, Norman H, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109(2 Pt 1):339-46
   PubMed Web of Science ®Google Scholar
• Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013;87(1):93-100
   PubMed Web of Science ®Google Scholar
• Nelson AL, Kaunitz A. Efficacy, safety and tolerability study of agile AG200-15 transdermal contraceptive delivery system. 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02158572?term=agile+transdermal+contraceptive&rank=3
   Google Scholar
• McGuire JL, Phillips A, Hahn DW, et al. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am J Obstet Gynecol 1990;163(6 Pt 2):2127-31
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2008;61(1-2):171-80
   PubMed Web of Science ®Google Scholar
• Kuhnz W, Blode H, Mahler M. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception 1994;49(3):255-63
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Rubin A, Flood L, et al. Pharmacokinetics,tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinyl estradiol and levonorgestrel. Horm Mol Biol Clin Investig 2011;6:231-40
   PubMedGoogle Scholar
• Archer DF, Stanczyk FZ, Rubin A, et al. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. Contraception 2012;85(6):595-601
   PubMed Web of Science ®Google Scholar
• Pierson RA, Archer DF, Moreau M, et al. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003;80(1):34-42
   PubMed Web of Science ®Google Scholar
• Israel R, Mishell DRJr, Stone SC, et al. Single luteal phase serum progesterone assay as an indicator of ovulation. 1972. Am J Obstet Gynecol 1997;176(2):490
   PubMed Web of Science ®Google Scholar
• Coney P, DelConte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol. Am J Obstet Gynecol 1999;181(5 Pt 2):53-8
   PubMed Web of Science ®Google Scholar
• Foegh M, Archer DF, Stanczyk FZ, et al. Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel. Contraception 2013;87(2):201-11
   PubMed Web of Science ®Google Scholar
• Archer DF, Stanczyk FZ, Rubin A, et al. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise. Contraception 2013;87(2):212-19
   PubMed Web of Science ®Google Scholar
• Abrams LS, Skee DM, Natarajan J, et al. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. Contraception 2001;64(5):287-94
   PubMed Web of Science ®Google Scholar
• Spona J, Feichtinger W, Kindermann C, et al. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception 1996;54(5):299-304
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Archer DF, Rubin A, et al. Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. Contraception 2013;87(6):744-9
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Portman D, Westhoff CL, et al. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial. Obstet Gynecol 2014;123(2 Pt 1):295-303
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002;77(2 Suppl 2):S13-18
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Torgal AH, Mayeda ER, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol 2010;116(2 Pt 1):275-83
   PubMed Web of Science ®Google Scholar
• Trussell J. Contraceptive failure in the United States. Contraception 2011;83(5):397-404
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Portman D, Westhoff CL, et al. Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill. Contraception 2015;91(3):204-10
   PubMed Web of Science ®Google Scholar
• Jick SS, Jick H. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception 2006;74(4):290-2
   PubMed Web of Science ®Google Scholar
• Jick SS, Jick H. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy 2007;27(2):218-20
   PubMed Web of Science ®Google Scholar
• Jick SS, Hagberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception 2010;81(5):452-3
   PubMed Web of Science ®Google Scholar
• Jick SS, Hagberg KW, Hernandez RK, et al. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010;81(1):16-21
   PubMed Web of Science ®Google Scholar
• Dore DD, Norman H, Loughlin J, et al. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010;81(5):408-13
   PubMed Web of Science ®Google Scholar
• Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007;197(2):134-e1-6
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. Bmj 2011;343:d6423
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Archer DF, Mishell DRJr, et al. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women. Am J Obstet Gynecol 2015;212(3):318.e1-8
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Portman D, Westhoff CL, et al. New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study. Contraception 2015;91(3):211-16
   PubMed Web of Science ®Google Scholar